LISATA THERAPEUTICS, INC.
LSTALisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
Drugs in Pipeline
8
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
LSTA Earnings Report
FQ end 2026-06
How LSTA's past catalysts played out
Auto-CD34+ cells
Chronic Myocardial Ischemia
therapeutic autologous dendritic cells
Melanoma (Skin)
CLBS16
Coronary Microvascular Dysfunction
NBS10
ST Segment Elevation Myocardial Infarction
CLBS14 (low-dose)
Myocardial Ischemia
CLBS03 Low Dose
Diabetes Mellitus
CLBS12
Critical Limb Ischemia
certepetide
Cholangiocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Auto-CD34+ cells | Phase 3 | Chronic Myocardial Ischemia | - | - |
therapeutic autologous dendritic cells | Phase 2 | Melanoma (Skin) | - | - |
CLBS16 | Phase 2 | Coronary Microvascular Dysfunction | - | - |
NBS10 | Phase 2 | ST Segment Elevation Myocardial Infarction | - | - |
CLBS14 (low-dose) | Phase 2 | Myocardial Ischemia | - | - |
CLBS03 Low Dose | Phase 2 | Diabetes Mellitus | - | - |
CLBS12 | Phase 2 | Critical Limb Ischemia | - | - |
certepetide | Phase 2 | Cholangiocarcinoma | - | - |
Melanoma (Skin)
1 drug in this indication
Critical Limb Ischemia
1 drug in this indication
Coronary Microvascular Dysfunction
1 drug in this indication
Chronic Myocardial Ischemia
1 drug in this indication
ST Segment Elevation Myocardial Infarction
1 drug in this indication
Cholangiocarcinoma
1 drug in this indication
Myocardial Ischemia
1 drug in this indication
Diabetes Mellitus
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in LISATA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in LISATA THERAPEUTICS, INC.'s (LSTA) pipeline across Phase 3, Phase 2. Its lead program is Auto-CD34+ cells (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LISATA THERAPEUTICS, INC.'s next FDA catalyst?→
LISATA THERAPEUTICS, INC.'s (LSTA) next tracked catalyst is a Acquisition expected July 24, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LSTA biotech catalysts?→
Add LSTA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LISATA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.